Trials / Not Yet Recruiting
Not Yet RecruitingNCT05055791
A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
A Phase Ⅰ/Ⅱ Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Efficacy of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 312 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is an open-label, multi-center, dose escalation, dose expansion, and cohort expansion phase I/II clinical study of SYHX1903 in patients with relapsed/refractory hematologic malignancies. This trial aims to evaluate the safety, tolerance, pharmacokinetics, and preliminary antitumor activity of SYHX1903 in patients with relapsed/refractory hematologic malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SYHX1903 | SYHX1903 tablets, orally, qd |
Timeline
- Start date
- 2021-12-29
- Primary completion
- 2026-06-20
- Completion
- 2026-09-20
- First posted
- 2021-09-24
- Last updated
- 2021-09-24
Source: ClinicalTrials.gov record NCT05055791. Inclusion in this directory is not an endorsement.